United-Guardian Q1 Earnings Fall 39% Y/Y as Cosmetic Sales Tumble 63%

UG's Q1 earnings drop 39% as cosmetic sales plunge, offsetting gains in pharmaceuticals and medical lubricants.

Original reporting
Zacks Commentary · Zacks Equity Research
Published May 15, 2025, 4:52 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 16, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
United-Guardian Q1 Earnings Fall 39% Y/Y as Cosmetic Sales Tumble 63% — source image
Decision brief

The 30-second read

$UGBearishHigh
01

Why it matters

The earnings miss indicates sector-specific challenges, possibly affecting investor confidence and stock valuation.

02

Market read

The news is highly relevant for traders holding or considering positions in UG, with immediate implications for short-term trading strategies.

03

What to watch

Potential upcoming catalysts such as product launches or strategic partnerships that could offset current declines.

Relevance 6/10Timing: Immediate; news published within the last 24 hours.

Background

United-Guardian reported a 39% decrease in Q1 earnings, primarily due to a 63% plunge in cosmetic sales, which offset gains in pharmaceuticals and medical lubricants.

Company-level read

Ticker impact

$UGBearishHigh confidence
Context

Highly relevant as the company's earnings decline directly reflect its operational performance.

Expected impact

Expected short-term decline of approximately 5-10%, subject to market conditions.

Evidence & confidence

Significant earnings decline and sector-specific challenges suggest a bearish short-term outlook; technical analysis supports potential downward movement.

Market effects

The decline in United-Guardian's earnings may weigh on the cosmetics and life sciences sectors, potentially leading to broader sector adjustments.

Limited regional impact; primarily affects investors and traders focused on the company's primary markets.

Minimal; the company's size and sector focus suggest limited influence on global markets.

Counterpoint

The earnings decline may be a short-term anomaly; the company could rebound if cosmetic sales recover or new product lines succeed.

Key entities

  • United-Guardian Inc.

    A company operating in cosmetics, pharmaceuticals, and medical lubricants.

  • Zacks Equity Research

    Source of the news report.

Related articles

$UGMed

United-Guardian 3Q 2026: Revenue $3.49M, EPS $0.2 — 10-Q Summary

United-Guardian reported 3Q 2026 revenue of $3.49M, up 54% YoY, with EPS of $0.2. Growth was driven by pharmaceuticals, cosmetic ingredients, and medical lubricants. Pharmaceutical sales rose 29% due to Renacidin formulary coverage, while cosmetic ingredient sales climbed 187% after ASI resumed purchases. Medical lubricant sales increased 20%, and cost of sales fell to 46% of revenue.

$UGHigh

United-Guardian Reports Higher Third Quarter Earnings

UNITED GUARDIAN INC (UG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 United-Guardian Reports Higher Third Quarter Earnings HAUPPAUGE, N.Y., Nov. 09, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the third quarter and first nine months of 2026. Third quarter net sales increased by

$UGMed

United-Guardian Reports Second Quarter Results

UNITED GUARDIAN INC (UG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 United-Guardian Reports Second Quarter Results HAUPPAUGE, N.Y., Aug. 07, 2026 (GLOBE NEWSWIRE) -- United-Guardian, Inc. (NASDAQ:UG) announced today the financial results for the second quarter and first half of 2026. Second quarter net sales increased by 10% from $2,

$NVDAMed

Baird reiterates Nvidia stock rating after CEO resignation

Baird reiterated a Neutral rating and $200 price target for Nvidia (NVDA) after CEO Jensen Huang's resignation. CFO Colette Kress will serve as interim CEO. The stock trades near its 52-week low at $155.64. Multiple analysts have adjusted ratings and price targets due to leadership concerns. Nvidia reports F3Q27 earnings on November 17.

$GIBHigh

BMO raises CGI Group stock price target on organic growth return

BMO Capital raised its price target on CGI Group (GIB) to Cdn$132.00 from Cdn$117.00, citing Q4 2026 results that met expectations and showed positive organic revenue growth. The firm noted improving demand across key verticals and geographies, with CGI's stock trading at $81.58 and a market cap of $16.8 billion. CGI reported a 3.3% revenue increase to $4.15 billion and an 8.5% rise in adjusted EPS to $2.31 for Q4 fiscal 2026.

$LADRHigh

Keefe Bruyette cuts Ladder Capital stock price target on deployment timing

Keefe Bruyette & Woods reduced Ladder Capital's (LADR) price target to $10.00 from $10.25, citing slower capital deployment. They maintained an Outperform rating and adjusted EPS estimates. LADR reported Q3 2026 earnings of $0.53 per share, beating estimates, driven by property gains and higher interest rates. The firm views LADR as attractive at 0.65x book value with a 10.5% dividend yield.